04/21/2026
The Food and Drug Administration is ramping up scrutiny of direct-to-consumer drug ads, raising new questions about regulation and the First Amendment.
After warning companies like Novo Nordisk, argenx, and Sobi, the agency is now seeking expanded authority to police ads it views as misleading. Supporters say tighter rules could curb costs and overprescription; critics argue they may run into constitutional limits on commercial speech.
Is this a necessary reform, or an attempt to regulate what can’t be banned outright?
Join us on April 27th for a discussion on the legal and policy stakes surrounding prescription drug advertising.
Ft. Paul Avelar, Jeff Stier (), and Dan Troy
Register:
The Trump Administration has been exploring new ways to tighten requirements for direct-to-consumer...